Cuba to begin industrial production of Hepatitis C vaccine

Cuba will shortly begin industrial production of the new Heber-NASVAC vaccine to treat Hepatitis C.  
   
The first batches of the drug are being packaged for trial to get a licence and certification of good practice as patients will receive the drug in liquid applications through the nasal cavity.  
  
The product is being manufactured at the National Centre for Bio-formulas in Cuba, but is the result of research by the Centre for Genetic Engineering and Biotechnology.